Diagnosis and treatment of prostate cancer.

Many controversies surround the management of prostate cancer to include screening practices, diagnosis, and treatment options. The lack of randomized prospective studies comparing the various definitive treatment modalities currently available occasionally can make the decision process challenging for patients and their providers. In this setting of controversy, the cost of treating clinically localized prostate cancer is significant. In the face of these unanswered questions, this article summarizes some important principles regarding the diagnosis and treatment of prostate cancer. This review is limited to the diagnosis and management of clinically localized disease.

[1]  J. Cheville,et al.  The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. , 2000, The Journal of urology.

[2]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[3]  M. Steiner,et al.  Minilaparotomy staging pelvic lymphadenectomy follow-up: a safe alternative to standard and laparoscopic pelvic lymphadenectomy , 1998, World Journal of Urology.

[4]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[5]  M. Gleave,et al.  Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. , 1996, Urology.

[6]  Schröder Fh,et al.  The European Screening Study for Prostate Cancer. , 1994 .

[7]  M. Banerjee,et al.  Lymph node size does not correlate with the presence of prostate cancer metastasis. , 1999, Urology.

[8]  D. Paulson,et al.  Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. , 1992, The Journal of urology.

[9]  H. Thaler,et al.  Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? , 1996, The Journal of urology.

[10]  R. Link,et al.  Indications for pelvic lymphadenectomy in prostate cancer. , 2001, The Urologic clinics of North America.

[11]  T. D. de Reijke,et al.  Current Status of Minimally Invasive Treatment Options for Localized Prostate Carcinoma , 2000, European Urology.

[12]  L Souhami,et al.  Controversies in prostate cancer radiotherapy: consensus development. , 2001, The Canadian journal of urology.

[13]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[14]  J. Moul,et al.  The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. , 2001, The Urologic clinics of North America.

[15]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[16]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[17]  C. Gatsonis,et al.  Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. , 1990, The New England journal of medicine.

[18]  P. Narayan,et al.  Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .

[19]  Michael N. Ferrandino,et al.  Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. , 2001, The Journal of urology.

[20]  S. Woolf.  Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.

[21]  P. Schellhammer,et al.  Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. , 1997, Urology.

[22]  W. Catalona,et al.  Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. , 1998, The Journal of urology.

[23]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[24]  J. Oesterling,et al.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. , 1995, The Journal of urology.

[25]  J. Oesterling,et al.  The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.

[26]  Kathleen N Lohr,et al.  Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[27]  R. Clayman,et al.  Staging pelvic lymphadenectomy for prostate cancer: a comparison of laparoscopic and open techniques. , 1993, The Journal of urology.

[28]  K. Shinohara,et al.  The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. , 2000, The Journal of urology.

[29]  P. Walsh,et al.  Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. , 2000, The Journal of urology.

[30]  J. Memmelaar.  Total prostatovesiculectomy; retropubic approach. , 1949, The Journal of urology.

[31]  R. Babaian,et al.  Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. , 1994, The Journal of urology.

[32]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[33]  J. Moul,et al.  A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group , 2001, BJU international.

[34]  Jerome P. Richie,et al.  Diagnosis and Staging of Prostate Cancer , 2003 .

[35]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[36]  W. Catalona,et al.  The nature of prostate cancer detected through prostate specific antigen based screening. , 1994, The Journal of urology.

[37]  R. Link,et al.  Laparoscopic radical prostatectomy , 2000, World Journal of Urology.

[38]  J. Oesterling,et al.  Age-specific reference ranges for serum prostate-specific antigen. , 1995, The Canadian journal of urology.

[39]  G H Hinkle,et al.  Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. , 1999, Urology.

[40]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[41]  Curtis Mettlin,et al.  Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers , 1993, CA: a cancer journal for clinicians.

[42]  M. Terris,et al.  Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. , 1998, The Journal of urology.

[43]  J. Nelson,et al.  The Treatment of Prostate Cancer. , 2001 .

[44]  T. Shankey,et al.  Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. , 1996, Urology.

[45]  M. Toublanc,et al.  Perineal versus retropubic radical prostatectomy for T1, T2 prostate cancer. , 1994, British journal of urology.

[46]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[47]  A. Zietman,et al.  Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. , 2000, JAMA.

[48]  P. Russo,et al.  Results of laparoscopic pelvic lymphadenectomy in patients at high risk for nodal metastases from prostate cancer , 1998, Annals of Surgical Oncology.

[49]  J. Nelson,et al.  The treatment of prostate cancer: an overview of current options. , 2001, Cancer practice.

[50]  V. Reuter,et al.  Clinical significance of repeat sextant biopsies in prostate cancer patients. , 1997, Urology.

[51]  P. Walsh,et al.  Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). , 1994, The Journal of urology.

[52]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[53]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[54]  L. Coupal,et al.  Prostate cancer: 12. The economic burden. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[55]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[56]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[57]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[58]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.